809
Participants
Start Date
November 27, 2023
Primary Completion Date
August 27, 2025
Study Completion Date
January 13, 2026
Cagrilintide
Cagrilintide will be administered subcutaneously.
Semaglutide
Semaglutide will be administered subcutaneously.
Tirzepatide
Tirzepatide will be administered subcutaneously.
Comprehensive Weight Ctrl Prog, New York
Washington Cntr Weight Mgmt, Arlington
Selma Medical Associates, Winchester
National Clin Res Inc., Richmond
Health Res of Hampton Roads, Newport News
Medication Mgmnt, LLC_Grnsboro, Greensboro
PharmQuest Life Sciences LLC, Greensboro
University of North Carolina, Chapel Hill
Accellacare_NC, Raleigh
Accellacare, Wilmington
Spartanburg Medical Research, Spartanburg
Coastal Carolina Res Ctr, North Charleston
Medical University Of South Carolina, Charleston
Hope Clin Res & Wellness, Conyers
Northeast Research Institute, Fleming Island
Jacksonville Ctr For Clin Res, Jacksonville
South Broward Research LLC, Miramar
Univ of Alabama Birmingham, Birmingham
Chambliss Clinical Trials LLC, Montgomery
Holston Medical Group_Bristol, Bristol
Holston Medical Group, Kingsport
New Venture Medical Research, Wadsworth
Midwest Inst For Clin Res, Indianapolis
Northern Pines Hlth Ctr, PC, Buckley
Endeavor Health, Skokie
Evanston Premier Hlthcr Res, Skokie
Great Lakes Clinical Trials, Chicago
StudyMetrix Research LLC, City of Saint Peters
Lynn Institute of Norman, Norman
Baylr Sctt White Rs Inst, Endo, Dallas
Velocity Clin Res, Dallas, Dallas
UT Southwestern Medical Center-CRU, Dallas
DCOL Ctr for Clin Res, Longview
UT Health University of Texas, Bellaire
Elligo Clin Res Centre, Austin
Amarillo Med Spec LLP, Amarillo
Univ of Colorado at Denver, Aurora
FDRC, Costa Mesa
Diablo Clinical Research, Inc., Walnut Creek
East West Med Res Inst, Honolulu
Rainier Clin Res Ctr Inc, Renton
Capital Clin Res Ctr,LLC, Olympia
The University of Penn Center, Philadelphia
Clinical Res Collaborative, Cumberland
Hillcrest Clinical Research, Simpsonville
Lead Sponsor
Novo Nordisk A/S
INDUSTRY